The pathogenesis of Alzheimer's disease (AD) has been mostly linked to aberrant amyloid beta (Aβ) and tau proteins metabolism, disturbed lipid/cholesterol homeostasis, and progressive neuroinflammation. Liver X receptors (LXR) are ligand-activated transcription factors, best known as the key regulators of cholesterol metabolism and transport. In addition, LXR signaling has been shown to have significant anti-inflammatory properties. In this brief review, we focus on the outcome of studies implicating LXR in the pathogenesis, modulation, and therapy of AD.
Introduction
Alzheimer's disease (AD) accounts for about 55 The fi rst evidence for the roles of LXR in neurodegeneration came from a study examining the neurological phenotype of mice with inactivated genes of both LXR isoforms [28] . Brains of these animals display several severe abnormalities including excessive lipid deposits, morphological changes of blood vessels and choroid plexus, proliferation of astrocytes, loss of neurons, and disorganisation of myelin sheets. Furthermore, mice with selective inactivation of the LXRβ isoform were shown to suff er from impaired motor coordination [29] and reduced number of neurons in the superfi cial cortical layers [30] . Zelcer et al. [31] 
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Effects of LXR agonists on neuroinflammation
Ample evidence suggests that brain inflammation plays an important role in the pathogenesis of AD (for reviews see [72] [73] [74] protein-1 (MCP-1) and others [31, 56, 65, [77] [78] [79] [80] .
In addition, treatment of immortalised murine microglial cells with the synthetic LXR agonist GW was shown to reverse LPSinduced inhibition of Aβ phagocytosis [31] . In vivo studies demonstrated that LXR agonists GW or TO90 reduce the neuroinflammatory response in experimental stroke [81] , NPC mice [62] , and in two lines of AD mice, i.e.
APP23 [56] and APP/PS1 [65] . In addition, administration of TO90 to APP/PS1 mice significantly decreased microglial activation [65] . Both in vitro and in vivo data suggested that LXR agonists suppress the production of proinflammatory molecules in brain cells by inhibiting nuclear factor-kappa B (NF-kB)
DNA-binding activity [65, 79] . Collectively, these results indicate that LXR agonists could alleviate AD pathology by acting on the brain inflammatory response.
Effects of LXR agonists on cognitive functions in AD mice
Memory loss is the earliest and the most common clinical manifestation of AD [82] . Mice overexpressing mutant APP and/or presenilins develop, along with AD-like neuropathology, also age-related memory deficits [83] . Different studies have shown that administration of synthetic LXR agonists restores behavioural phenotype in these animals. In particular,
short-term administration of TO90 or GW (7 or 6 days, respectively) [57, 58] tasks [59] . Long-term (6-9 weeks) application of TO90 restored object recognition and object location memory also in aged APP SL xPS1 mice [61] , and slightly improved spatial learning in APP23 -mouse expressing human APP751 isoform containing the Swedish (K670N/M671C) familial AD mutation; Tg2576 -mouse expressing human APP695 isoform containing the Swedish (K670N/M671C) familial AD mutation; APP/PS1 -mouse coexpressing a chimeric human/mouse APP650 isoform containing the Swedish (K670N/M671C) familial AD mutation and the human PS1 gene deleted for exon 9; APPSLxPS1mut -mouse coexpressing human APP gene carrying the Swedish/London familial AD mutations and mutant PS1 (M146L); TO90 -TO901317; GW -GW3965. [32] . Improvement in Morris water maze tasks was obtained also in APP/PS1 mice treated for 30 days with TO90 [65] . TO90 administration was further shown to reduce memory deficits caused by high-fat diet in APP23 mice [70] .
MOVING OF LXR AGONISTS TO CLINICAL PRACTICE
In spite of favourable effects demonstrated in AD mice (summarised in Figure 1) , moving of LXR agonists to clinical practice has been hampered owning to adverse side effects, the most serious being hepatic steatosis and increased production of atherogenic triacylglycerol-rich VLDL particles [84] . LXRs form permissive heterodimers with retinoid X receptors (RXRs), the receptors of 9-cisretinoid acid [85] . within only 72 hours [86] . Unfortunately, none of the follow-up studies could replicate the effect of bexarotene on Aβ plaques [87] [88] [89] [90] and only two out of four were able to confirm the effect on soluble Aβ levels [87, 90] , one of them reproducing also cognitive improvements [87] .
However, the FDA-approved formulation of bexarotene, Targretin, has entered phases I and II clinical trials in AD patients [91] , regardless of this inconstancy in preclinical results. observed that some aspects of LXR physiology differ between humans and rodents [92, 93] . In order to fully understand effects of LXR agonists and modulators on AD pathogenesis, further studies are needed, particularly in experimental models more relevant to human physiology.
CONCLUSIONS
